RxDoctor Payments Data

Evan Feldman, MD

Colon & Rectal Surgery · Atlanta, GANPI 1750530630

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,776 of the $6,624 with a category attached, or 72.1%. 35 manufacturers reported payments, led by Intuitive Surgical at 27.7% of the total. Reporting peaked in 2019 at $2,270 and has fallen 81.4% since, to $422 in 2025.

$6,624in general payments, 2019–2025

Across 132 payments — averaging $50.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$2K
  • Medtronic$962
  • Musculoskeletal Transplant Foundation Inc.$935
  • Stryker$630
  • Davol Inc.$290
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$274
  • plus $2K from 29 others

What the payments were for

  • Travel & lodging$1,84828%
  • Food & beverage$4,77672%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,624 in reported general payments places this provider in the 60th percentile of 66 colon & rectal surgery providers in Georgia.

See all colon & rectal surgery providers in Georgia

Medicare billing

Part B allowed, 2024
$176,938
Medicare patients
239
Services billed
642

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GattexTeduglutide12$531,216
ClenpiqSod Picosulf/Mag Ox/Citric Ac26$4,474
Ondansetron OdtOndansetron82$429
Lidocaine12$349
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav12$299
LoperamideLoperamide Hcl13$297
Oxycodone Hcl59$271
Neomycin Sulfate51$259
Metronidazole58$129
Ondansetron Hcl34$120
Ciprofloxacin Hcl11$90
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen21$60

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gattex$153$531,21612 claims
Ferring Pharmaceuticals Inc.Clenpiq$130$4,47426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 66 colon & rectal surgery providers in Georgia.

Other colon & rectal surgery in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →